In Brief: Quidel/Bayer
This article was originally published in The Gray Sheet
Executive Summary
Quidel/Bayer: Ink 5-year collaborative agreement under which San Diego, California-based Quidel will develop and supply automated versions of its current line of manual immunodiagnostic pregnancy, strep, H. Pylori and mononucleosis tests for use with Bayer's Clinitek line of urine chemistry analyzers. Bayer expects the first test to be available in April 1997 following FDA 510(k) clearance and anticipates development of additional tests in six-month intervals thereafter. The tests will be priced competitively with manual versions, with a "slight premium" for the added features of instrument result determination and recordability, Bayer says...
You may also be interested in...
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.